Evidence map›Paper›PMID 28638004›Full record

ArticleFukushima journal of medical science2017

Modification of the HCMV-specific IFN-γ release test (QuantiFERON-CMV) and a novel proposal for its application.

Takahiro Kobayashi, Jun-Ichi Sato, Kazufumi Ikuta, Ryoko Kanno, Kyoko Nishiyama, Tetsuo Koshizuka, Ken Ishioka, Tatsuo Suzutani

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Fukushima journal of medical science, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Takahiro KobayashiDepartment of Microbiology, Fukushima Medical University School of Medicine, Fukushima.
Jun-Ichi SatoDepartment of Microbiology, Fukushima Medical University School of Medicine, Fukushima.
Kazufumi IkutaDepartment of Microbiology, Fukushima Medical University School of Medicine, Fukushima.
Ryoko KannoDepartment of Microbiology, Fukushima Medical University School of Medicine, Fukushima.
Kyoko NishiyamaDepartment of Microbiology, Fukushima Medical University School of Medicine, Fukushima.
Tetsuo KoshizukaDepartment of Microbiology, Fukushima Medical University School of Medicine, Fukushima.
Ken IshiokaDepartment of Microbiology, Fukushima Medical University School of Medicine, Fukushima.
Tatsuo SuzutaniDepartment of Microbiology, Fukushima Medical University School of Medicine, Fukushima.
Fukushima Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human cytomegalovirus (HCMV) is universally distributed among humans without any adverse effects; however, it induces severe diseases in immunocompromised patients such as organ transplant recipients and AIDS patients. To manage these immunocompromised patients, an easy clinical examination for the monitoring of disease risk is required. In this study, we modified the interferon-γ (IFN-γ) release test (QuantiFERON

Indexed as

AdultAntibodies, ViralAntigens, ViralCytomegalovirusFemaleHumansImmediate-Early ProteinsInterferon-gammaMaleMiddle AgedPhosphoproteinsViral Matrix ProteinsYogurtAntibodies, ViralAntigens, Viralcytomegalovirus matrix protein 65kDaIE1 protein, cytomegalovirusImmediate-Early ProteinsInterferon-gammaPhosphoproteinsViral Matrix ProteinsCellular immunityHuman cytomegalovirusInterferon-γ

Identifiers

PMID28638004
PMCPMC5597525
OpenAlexW2697327832

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.